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with aging, which resulted in little attention being given 
to sexual behavior and treatment of sexual dysfunctions 
in the older population. However, in the current era it is 
known that as life expectancy improves, both men and 
women are seeking to preserve their sexuality into old age. 
While the appreciation of sexuality persists with aging, a 
decline in sexual activity is typically seen with, and can 
be attributed to both general health problems as well as 
specific sexual dysfunctions. In a large US study, the pro-
portion of males who were sexually active declined from 
83.7% in the age group 57–64 years to 38.5% in the age 
group 75–85 years  [1] . In a smaller pilot study in a cohort 
of 50 patients with a mean age of 81 years, Smith et al. [2] 
reported that the main reason for being sexually inactive 
in older men was erectile dysfunction (ED), the condition 
defined as the persistent inability to attain and maintain 
penile erection sufficient for sexual intercourse  [3] . It is 
likely the most thoroughly studied sexual dysfunction in 
men and the most common sexual complaint of men pre-
senting to their healthcare providers  [4] . The advent of 
safe oral therapy for the treatment of ED has brought at-
tention to the disease and likely results in increased treat-
ment-seeking behavior, also in the aging male. Despite the 
overwhelming success of these oral phosphodiesterase-5 
inhibitors (PDE5I), the demand for pharmacotherapeutic 
and surgical options for ED continues to rise as a result of 
the increased proportion of elderly in the population as 
well as the increasing recognition that approximately one 
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 Abstract 
 Before the 20th century, individuals often did not live be-
yond the reproductive years, and sexuality of the elderly was 
not an issue. However, in the current era it is known that as 
life expectancy improves, both men and women are seeking 
to preserve their sexuality into old age. While the apprecia-
tion of sexuality persists with aging, a decline in sexual activ-
ity is typically seen with, and can be attributed to both gen-
eral health problems as well as specific sexual dysfunctions. 
Erectile dysfunction is the most frequently diagnosed sexual 
dysfunction in the older male population. This mini-review 
provides an overview of contemporary literature concerning 
epidemiology, pathophysiology, assessment and treatment 
of erectile dysfunction in the aging male. 
 Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Before the 20th century, individuals often did not live 
beyond the reproductive years, and sexuality of the elder-
ly was not an issue. More recently, it was generally as-
sumed that a loss of sexuality was natural and inevitable 
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third of ED patients do not respond to PDE5I  [5] . This is 
especially applicable to the older patient with multiple 
pathophysiological alterations in erectile mechanisms. 
Therefore, ED remains a topic of interest to physicians 
treating the aging and older male. This review will ad-
dress erectile biology and age-related changes thereof, the 
prevalence of ED, its etiological factors in the older popu-
lation, and contemporary treatment options geared to-
ward the treatment of ED in aging and aged males.
 Prevalence and Etiology 
 Notwithstanding variations in definitions and meth-
odology, various large-scale studies substantiate the glob-
al presence of ED, and its close relationship to aging. The 
Massachusetts Male Aging Study for example, is a large-
scale longitudinal project investigating the effects of ag-
ing on male sexual health, among other domains. The 
authors reported a combined prevalence of minimal, 
moderate and complete impotence of no less than 52% 
 [6] . The prevalence of complete impotence tripled from 5 
to 15% between subject ages 40 and 70 years  [6] . In the 
European Male Aging Study (EMAS), a collaborative ef-
fort of eight European centers investigating ED in a male 
population aged 40–79 with a mean age of 60 years old, 
30% of the entire EMAS sample reported ED  [7] . The 
prevalence of ED was higher in the older age groups, 
peaking in men 70 years and older (64%). It was further 
shown that men in higher age groups, although more of-
ten affected, were less concerned with the presence of ED 
 [7] . Approximately 617,000 new cases occur annually in 
men aged 40–69 in the US alone  [8] .
 ED is strongly associated with advancing age. It logi-
cally follows that ED is therefore highly prevalent in the 
older population  [9] . With the rapidly expanding aging 
population and the increase in life expectancy, an increase 
in the prevalence of ED is expected in the years to come. 
It is estimated that by 2025, 9.5% of the worldwide popula-
tion will be men older than 65 years of age  [10] . By then, 
the number of men suffering from ED will reach 322 mil-
lion worldwide. The relationship between age and ED is 
illustrated by the fact that the prevalence of ED rises 
steadily with age from 30.7% in men aged 57–64 years, to 
43.3% in men aged 75–85 years  [11] . In other studies, prev-
alence rates up to 77.5% are mentioned in patients aged 75 
years and older  [12] . However, not only the prevalence, but 
also the severity of ED increases with advancing age. The 
relationship between aging and ED is in part based on the 
increasing morbidities aged men experience, such as hy-
pertension, vascular disease, chronic kidney disease, de-
pression, and many others. Polypharmacy further con-
tributes to the development of ED in the aging population. 
These concurrent conditions contribute to the develop-
ment of ED via a multitude of pathways, aside from the 
changes induced by the process of aging itself.
 Physiology and Pathophysiology 
 Physiology 
 For a good understanding of pathophysiological pro-
cesses and treatment options for ED in aging men, we 
first briefly discuss the basic physiological processes in-
volved in erectile biology. For a more elaborate discus-
sion, we refer the reader to references  [13] and  [14] . Penile 
erection is a complex neurovascular phenomenon under 
hormonal control. Upon sexual arousal, pro-erectile im-
pulses are generated in the parasympathetic erection cen-
ters of the limbic system and the hypothalamus. These 
impulses are mediated by predominantly dopaminergic 
neurons, whereas serotonin is the principle erection-in-
hibiting neurotransmitter. These central erectile mecha-
nisms partially provide an explanation for diminished 
sexual function in aging-related central neurological 
conditions such as Parkinson’s disease, in which dopami-
nergic neurotransmission is impaired. Dopamine-con-
taining nerve endings impinge on oxytocinergic cell bod-
ies in the paraventricular nucleus which project, in turn, 
to extra-hypothalamic brain areas such as the hippocam-
pus, the ventral medulla, and the spinal cord, which con-
tains the sacral spinal erection centre in the S2–S4 region. 
In addition to central pathways, an erectogenic stimulus 
may originate in response to direct tactile stimulation of 
the penis, exciting afferent sensory neurons to the sacral 
spinal erection center.
 Efferent neurons pass anterior and lateral to the rec-
tum as the nervi erigentes to relay with nonadrenergic, 
noncholinergic fibers in the hypogastric plexus. These fi-
bers run through the cavernous nerves which are located 
mainly dorsolateral to the prostate, and perforate the uro-
genital diaphragm to enter the cavernous bodies at the 
level of the crura. A central or reflexogenic neural stimu-
lus leads to a release of nitric oxide (NO) from nerve ter-
minals of the cavernous nerves in the corpus caverno-
sum. In addition, NO is released from the endothelium in 
response to release of acetylcholine and putatively also in 
response to the shear stress exerted at the walls of the pe-
nile sinusoids filling with blood. NO, which is gaseous in 
nature, diffuses into the cavernous smooth muscle cells 
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where it upregulates cyclic guanosine monophosphate 
(cGMP), which acts as a second messenger and initiates a 
chain of reactions ultimately resulting in a decrease in 
intracellular calcium and relaxation of the smooth mus-
cle ( fig. 1 ). Other mechanisms of smooth muscle relax-
ation are mediated by cGMP after binding of endogenous 
prostaglandins to their receptors ( fig. 1 ). The relaxation 
of smooth muscle in the walls of the sinusoids and in the 
arterial walls allows rapid blood flow into the cavernosal 
sinusoids. The subsequent engorgement of the penis 
compresses the emissary veins, which drain the sinusoi-
dal blood, against the tunica albuginea thereby halting 
venous outflow. A further increase in penile rigidity is 
established by contraction of the striated ischiocavernous 
muscles, increasing intracorporeal pressure to several 
hundreds mm Hg.
Endothelial cell
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channel
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Ca2+ ATPase
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SR
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Relaxation
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 Fig. 1. Pathways leading to penile smooth muscle relaxation and 
erection. NO is released from nerve terminals in the corpus cav-
ernosum in response to a neural stimulus and from the endothe-
lium in response to the release of acetylcholine (ACh) and to the 
shear stress elicited by increased blood flow in the corporeal si-
nusoids. NO binds to soluble guanylate cyclase (sGC) and thereby 
activates this enzyme, which catalyses the breakdown of guano-
sine triphosphate (GTP) into cGMP. This pathway, the target of 
PDE5-inhibition, is depicted in green. Other pathways, which are 
initiated by PGE1, activate a G-protein (G)-coupled receptor, 
leading to activation of adenylil cyclase (AC), which catalyses the 
breakdown of adenosine triphosphate (ATP) into cyclic adenosine 
monophosphate (cAMP). This pathway, and thus target for intra-
cavernosal injection of prostaglandin, is depicted in red. cGMP 
and cAMP activate protein kinase G and A, respectively, which 
modulate potassium and calcium channels in the cell membrane, 
and the inositol triphosphate receptor (IP3-R) and the calcium-
ATPase pump in the membrane of the sarcoplasmatic reticulum 
(SR). These events lead to a lowering of the cytosolic calcium con-
centration, which causes dissociation of calcium from calmodu-
lin. Calmodulin in turn dissociates from myosin light chain ki-
nase, thus inactivating it in turn leading to smooth muscle relax-
ation, and ultimately, to penile tumescence. Figure and legend 
adapted from Albersen et al.  [14] . 
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 The above described pro-erectogenic parasympathetic 
mechanisms are counterbalanced by sympathetic input 
from the cavernous nerves. The sympathetic nervous sys-
tem is active when the penis is flaccid and carries out its 
anti-erectogenic effects by the release of norepinephrine 
from the nerve terminals, which stimulates the   1 -adren-
ergic receptor on the cavernosal smooth muscle cells. 
This activates the phospholipase C pathway, enhancing 
influx of calcium and an increasing smooth muscle tone. 
The contraction induced by norepinephrine is potenti-
ated by endothelin-1, which is released from the endothe-
lial cells lining the sinusoidal spaces in response to adren-
ergic stimulation.
 Pathophysiology 
 As stated above, ED in aging males is the result of var-
ious factors which exert negative effects on multiple levels 
in erectile biology. Herein, we focus on those processes 
typically involved in aging. However, many other disor-
ders that are prevalent in aged males further contribute 
to the development of ED by interfering with erectile bi-
ology at multiple levels.
 First, in the aging male the vascular supply to the penis 
is compromised. It has been shown in the rat that the in-
ternal pudendal artery is subject to an accelerated aging 
process compared to other vessels like the renal artery and 
the aorta. It was postulated that this effect was a conse-
quence of the episodic significant increase in the hemody-
namic load these small diameter vessels have to withstand. 
Morphological assessments showed medial thickening, 
and significantly reduced capacity for penile blood flow 
 [15] . In humans, postmortem studies have revealed that 
aging is associated with increasing degrees of atheroscle-
rotic vascular alteration in the arterial bed of the penis  [16] .
 Second, aside from morphological changes, in multi-
ple human arteries,   1 -adrenergic receptor expression in-
creases, and the relative proportion of   1 -adrenergic re-
ceptor subtypes is modulated by aging. These changes are 
likely applicable to the human prostatic, bladder, and 
erectile tissue  [17] . These changes translate functionally 
in a reduced efficacy of phenylephrine in inducing con-
tractions of vascular smooth muscle strips in-vitro which 
was significantly greater for those isolated from the cor-
pus cavernosum of older ( 1 60 years) men with ED than 
for those isolated from younger ( ! 60 years) men with ED. 
These results underline that aging also plays a role in ad-
renergic sensitivity in patients with ED  [18] . Another fac-
tor contributing to impaired vasodilation in the corpus 
cavernosum and the penile arterial supply of the older 
man is endothelial dysfunction. It has been shown that 
the reduction in endothelial function occurs steadily 
with age in males, whereas in females the age-dependent 
reduction in endothelium-dependent vascular respon-
siveness becomes obvious only after the menopause  [19] . 
Endothelial dysfunction is one of the main common de-
nominators that link ED and cardiovascular disease, and 
the two disorders share various risk factors, of which age 
is the capital one. Furthermore, in the process of aging, 
the number of risk factors for endothelial dysfunction is 
augmented by an increase in comorbid conditions such 
as hypertension, dyslipidemia and diabetes. Endothelial 
dysfunction in aging has, among other factors, been at-
tributed to the presence of NO scavengers in the corpus 
cavernosum, the most obvious candidates being superox-
ide anions, production of which is augmented in ageing 
endothelial cells  [19] . This causative link is further 
strengthened by the fact that the decrease in endotheli-
um-dependent vasodilatation with age in humans can be 
prevented by inhibitors of cyclooxygenase and vitamin C, 
both powerful antioxidants  [19] . The presence of reactive 
oxygen species results in an inflammatory state of the 
endothelium resulting in predisposition to plaque forma-
tion and atherosclerosis, thereby further reducing blood 
flow to the erectile tissue. The changed state in the aged 
endothelium further results in the inactivation of eNOS 
through a decrease in phosphorylation of its positive reg-
ulatory site and an increase in phosphorylation of its neg-
ative regulatory site  [20] . Not only the activity of eNOS is 
decreased, also the penile expression of eNOS is dimin-
ished in aged rats. The latter might be attributable to an 
increase in apoptosis of the endothelium which is not suf-
ficiently replenished due to a lack of regeneration by en-
dothelial progenitor cells  [21] . Thus, a dysfunctional pe-
nile endothelium results in a decreased release of NO re-
sulting in an increased vascular and sinusoidal smooth 
muscle tone.
 Third, not only the endothelial supply of NO to the 
cavernosal smooth muscle is diminished. Penile nNOS 
activity and expression are diminished in aged animals, 
further reducing the availability of NO to the erectile tis-
sue and thereby contributing to an increased sinusoidal 
and arterial smooth muscle tone. This is illustrated by a 
decreased intracavernosal pressure upon electrostimula-
tion of the cavernous nerve in rodents. The findings of 
decreased nNOS and eNOS expression and activity are 
further supported by a decline in cGMP content in aged 
rat penises  [22] .
 Fourth, both the penile extracellular matrix and the 
cavernous smooth muscle cells also are affected by aging. 
The percentage of smooth muscle steadily decreases with 
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aging  [23] . Furthermore, corpora cavernosa of aged men 
demonstrated excessive deposition of collagen fibers 
which resulted in corporal fibrosis. These changes are 
similar to those observed in the media of the penile arter-
ies  [24, 25] . It has been postulated that these histologic 
changes in the aged corpora, like endothelial dysfunc-
tion, are caused by increased oxidative stress and/or oth-
er profibrotic factors that stimulate smooth muscle apop-
tosis and collagen deposition  [16] . Changes in smooth 
muscle content and extracellular matrix proteins, par-
ticularly collagen and elastin, can provoke mechanical 
 alterations of the penis, which reduce its elasticity and 
compliance. These alterations result in an impaired ex-
pandability of the corporeal tissue, and therefore the 
mechanism by which the expanding sinusoids compress 
the emissary veins against the tunica albuginea becomes 
defective. This results in corporeal venous leakage which 
typically presents as the inability to maintain an erection 
as is frequently seen in the aged male.
 Finally, a factor contributing to the above-described 
changes in smooth muscle and collagen content of the 
corpus cavernosum is androgen deficiency. This condi-
tion is highly prevalent in aging males and has also been 
linked to loss of smooth muscle mass in the penis. An-
drogen deprivation in castrated animals results in a sig-
nificant reduction in trabecular smooth muscle content 
and in a marked increase in connective tissue deposition 
 [26] . These structural alterations are also associated with 
loss of erectile function. Ultrastructural studies demon-
strated that cavernosal smooth muscle lining the sinu-
soids in castrated animals appeared disorganized, 
whereas in the intact animals the smooth muscle cells 
exhibited normal morphology  [27] . In addition to the al-
terations in smooth muscle and connective tissue, fat-
containing cells have been observed in the subtunical re-
gion of penile tissue sections from orchiectomized ani-
mals  [28, 29] , potentially contributing to corporeal 
veno-occlusive dysfunction in aged men. Furthermore, 
the presence of androgens regulates the normal mor-
phology and function of the cavernous nerves, and keeps 
the endothelium in a healthy condition. Thus, androgen 
deficiency in aged males complicates erectile biology at 
multiple levels.
 Assessment of ED 
 While ED used to be evaluated and treated in a dis-
ease-centered approach, like is common in many other 
fields in medicine, the current approach of ED is rather 
patient-centered. In this approach the physician con-
sciously adopts the patient’s perspective, and respects his 
and the partner’s values and expectations  [13, 30] . ED in 
the aging male is more often than not of multifactorial 
origin and therefore in need of a holistic assessment. The 
initial evaluation of ED should include a complete medi-
cal, psychosocial and sexual history. As the evaluation of 
ED in the aging male is patient-centered, the goal should 
be not only to identify the specific erectile problem and 
potential underlying diseases, but more important, to get 
an idea of the patient expectations and reasons for con-
sultation.
 Medical History 
 The goal of history-taking should be to not only un-
derstand the specific erectile condition, but also to iden-
tify possible underlying and reversible or treatable disor-
ders  [30] . A thorough medical assessment is mandatory 
in the evaluation of erectile complaints in all patients, but 
is particularly important in the older male and in patients 
at intermediate and high risk for cardiovascular disease. 
These patients should undergo cardiovascular assess-
ment before continuation of sexual activity and before 
initiating therapy for ED  [31] . Patients are therefore sub-
jected to a risk stratification which determines whether 
cardiovascular status permits sexual activity and phar-
macological treatment of ED. Underlying conditions 
such as depression, diabetes, late-onset hypogonadism, 
metabolic syndrome, and medication/surgically induced 
causes of ED should be ruled out and if present, addressed 
accordingly. A thorough review of medications should 
identify the use of agents known to cause or exacerbate 
ED (such as antidepressants, antiandrogens, thiazides 
and beta-blockers). It is furthermore very important to 
assess for use of nitrate donors, which are absolute con-
traindications for therapy with PDE5 inhibitors, and 
some alpha-blockers which need a certain time interval 
between their use and the use of PDE inhibitors.
 Sexual History 
 A thorough sexual history-taking can help in under-
standing the causes of ED. An adequate sexual history 
should include information about the current sexual 
relationship(s), both the emotional as well as the physical 
status of the patient and the partner, and the exact reasons 
for consulting unique to the patient or the couple  [30] . De-
scriptive measures such as rigidity and duration of noc-
turnal erections, erections during masturbation and erec-
tions following sexual arousal should be discussed, as they 
can give clues about the etiology of ED. The onset of the 
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problem and any situational factors that are linked to the 
occurrence of ED should be identified. It is necessary to 
determine whether ED is the primary sexual problem or 
if some other aspects of the sexual response cycle (desire, 
ejaculation, orgasm) are involved. Problems with arousal, 
ejaculation and difficulty reaching orgasm may be signs 
of underlying sexual dysfunctions such as late-onset hy-
pogonadism, which is highly prevalent in this particular 
group of patients  [9] . The impact of ED and other sexual 
dysfunctions on both general well-being and sexual satis-
faction is an important issue, not only for the patient him-
self, but also for the partner. The intrapersonal impact of 
ED should not be underestimated, and therefore ideally is 
addressed in the presence of the partner. Open communi-
cation within the couple should be stimulated. As patients 
and their partners are likely bothered by discussing sexu-
al issues, it is important that the clinician maintains an 
attitude of comfort and flexibility throughout the evalua-
tion process  [30] .
 The use of standardized questionnaires such as the In-
ternational Index of Erectile Function can be useful in-
struments in assessing the severity of ED, in screening for 
other sexual dysfunctions, and in evaluating treatment 
outcome. However, questionnaires should not substitute 
for a detailed sexual history.
 Physical Examination 
 Physical examination is an essential part of the assess-
ment of ED, although it rarely identifies a specific cause. 
Like medical history taking, the physical exam is helpful 
in finding signs of underlying or comorbid conditions. It 
therefore should include a general screening examination, 
including cardiovascular, neurologic, and metabolic health 
status. Blood pressure and heart rate should be measured 
if they have not been assessed in the previous 3–6 months. 
Particular attention should be given to examination of the 
genitals and secondary sex characteristics. Deformities 
such as micropenis, chordee and Peyronie’s disease may be 
identified by careful examination of the penis. Testing for 
genital and perineal sensation and the bulbocavernosus re-
flex is useful in assessing a possible neurogenic compo-
nent. Assessment of testicular size is of importance as 
small testes and regression of secondary sex characteristics 
may indicate underlying hypogonadism  [30] .
 Laboratory Investigation 
 Fasting glucose, lipids, and hormonal profiles are typi-
cally included in the laboratory investigation of the patient 
complaining from ED. In line with history taking and 
physical examination, these tests are performed to iden-
tify specific causes like hypogonadism, or to assess the role 
of medical comorbidities such as diabetes and hyperlipid-
emia. The laboratory investigation may identify treatable 
conditions or previously undetected medical illnesses that 
may contribute directly to ED. Additional laboratory tests 
may be performed at the discretion of the physician based 
on the medical history and/or physical exam.
 Technical Investigation 
 Generally when treating any patient with any disorder, 
a specific diagnosis is needed to formulate a treatment 
plan. In most cases of ED, treatment can be initiat-
ed without extensive technical investigation. Excluding 
some minimally invasive technical investigations such as 
color duplex ultrasound, the value of additional technical 
investigations in the older patient is limited, as the impli-
cations of the results do not change therapy significantly 
in this specific population. Investigations such as dynam-
ic infusion cavernosometry, cavernosography, arteriog-
raphy and neurophysiologic testing are reserved for as-
sessment of younger patients in whom vascular or neuro-
logic reconstructive surgery might be indicated. Cases 
that might need further specialist investigations include 
patients suffering from Peyronie’s disease, complex neu-
ropsychiatric problems, severe relationship issues, com-
plicated endocrinological disorders, failure of initial 
treatment or previous pelvic trauma.
 Treatment 
 Nonpharmacological Treatment 
 Counseling 
 Before the initiation of treatment, it is important to set 
realistic outcome goals in open communication with the 
patient and his partner. Reviewing the findings of the ini-
tial evaluation with the patient or the couple can be used 
as a starting point to educate about the anatomy and 
physiology of sexual function and to provide appropriate 
understanding of the patient-specific pathophysiology of 
ED. Current oral pharmacological treatments for ED do 
not ‘cure’ ED but can generally be relied upon to improve 
erectile function in patients without important comor-
bidities or underlying disorders such as diabetes, or after 
radical prostatectomy. It should be clarified to the older 
patient that due to comorbidities and multiple patho-
physiologic changes in the penis, vasculature and ner-
vous system, a fully rigid erection will be hard to accom-
plish with the use of oral pharmacotherapy. The patient 
and his partner should further be educated about possible 
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pharmacological and nonpharmacological treatment op-
tions ( table 1 ). The choice of treatment should be made by 
the patient and partner supported by the physician, who 
ideally does not assume an authoritative role in this deci-
sion process  [30] . Alternative forms of intimacy that do 
not rely on penetrative sexual intercourse and satisfac-
tion associated with these activities are further discussed. 
Satisfaction with sex life is directly related to metal health; 
this implies that if men with ED can learn to be satisfied 
with other forms of intimacy, mental health could be pre-
served  [32] . Referral to a sexologist or relationship thera-
pist for more extensive counseling might be indicated if 
intrapersonal problems are encountered. Furthermore, 
in some patients with psychogenic or mixed psychogenic-
organic ED, specialized psychosexual therapy may help 
relieve anxiety and remove unrealistic expectations as-
sociated with medical or surgical therapy. 
 Lifestyle Changes 
 Obesity, sedentary lifestyle and cigarette smoking are 
the most common lifestyle factors that cause or contrib-
ute to ED. Therefore, patients should be educated about 
the beneficial effects of weight loss, increasing exercise, 
and quitting smoking on erectile function. Furthermore, 
the addition of a statin to the therapy of men suffering 
from ED and hypercholesterolemia has shown beneficial 
effects on erectile function  [33] .
 Medication Changes 
 Multiple medications can cause, or contribute to pre-
existing ED. Diuretics, particularly thiazides, but also an-
tihypertensives including   -adrenergic antagonists and 
nonspecific   -antagonists have frequently been described 
to cause or worsen ED. Furthermore, tricyclic antidepres-
sants have been linked to both loss of libido up to 70% and 
ED in 1.7–6.4%  [34, 35] . These drugs are known to in-
crease ejaculatory latency time and are currently even pre-
scribed for the treatment of premature ejaculation. An-
drogen blockade in the case of prostate cancer treatments 
has similar effects on erectile function and libido. Aside 
from these specific drugs, a variety of compounds such as 
antihistamines, nonsteroidal anti-inflammatory drugs, 
anti-arrythmics and drugs for the treatment of Parkin-
son’s disease have been linked to ED on a more anecdotal 
Table 1.  Pharmacological and mechanical treatment options for ED
Product Dose Dosing
frequency
Advantages Side effects
Sildenafil
Vardenafil
Tadalafil
25, 50, 100 mg
2.5, 5, 10, 20 mg
2.5, 5, 10, 20 mg
on demand
or daily
most effective oral pharmacotherapy; 
safe; available on demand as well as 
continuous low dose
(vardenafil 2.5 mg, tadalafil 2.5 mg)
cost, headache, facial flushing,
nasal congestion, myalgia, back pain, 
and blurred or disturbed vision
Yohimbine 5–15 mg three times 
daily
natural product limited evidence; anxiety,
hypertension, tachycardia
Apomorphine SL 4 mg on demand rapidly absorbed, available for 
patients taking nitrates
lower efficacy than PDE5-I; 
nausea, headache and dizziness
PGE1
Phentolamine
Papaverine
VIP
5–40 g1
1.25–2 mg1
30–110 mg1
25 g1
on demand direct action, broad efficacy, safety;
effective in neurogenic ED
priapism, painful erections, penile 
fibrosis; injection training needed
MUSE 125, 250, 500, 
1,000 g
on demand no injection needed hypotension, syncope, urethral 
burning or pain in the patient,
vaginal irritation in partner
Vacuum
constriction
device
on demand minimally invasive, not expensive unnatural erection; absence of 
spontaneity; bruising, pain; cold 
penis; pivoting at constriction band
Penile prosthesis permanent high success and satisfaction rates complications, irreversible
1  Doses need to be adjusted for combination therapy.
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basis. In most situations, changing to a different class of 
drug, if possible, is a feasible first step  [30] . Regarding an-
tihypertensives, newer agents such as calcium-channel 
blockers and angiotensin-converting enzyme inhibitors 
may reverse ED in some patients, and switching to an   1 -
specific agonist, such as doxazosin, preserves erectile 
function. Angiotensin receptor blockers, such as valsar-
tan, losartan and candesartan may further have beneficial 
effects on erectile function. Regarding antidepressants, 
substitution, drug holidays and dosage reduction have 
been proposed  [35] . This should be done in agreement 
with the physician prescribing the specific medication. 
Aside from medications, recreational and frequently 
abused drugs such as alcohol, cocaine, marijuana, am-
phetamines and opiates have been linked to ED, and the 
patient should be counseled about these facts  [30] . As step-
by step review of the patient medications should be per-
formed when treating ED, to investigate whether nones-
sential drugs with negative impact on erectile function 
can be abandoned, and whether essential drugs can be 
replaced by their counterparts or drugs from another 
family with less impact on erectile function.
 Pharmacotherapy 
 Selective PDE5I 
 PDE5I are intracellular signal amplifiers. They are 
nonhydrolysable analogs of cGMP and exert their benefi-
cial effects on smooth muscle relaxation by competitively 
binding to the catalytic site of PDE5, the enzyme respon-
sible for breakdown of cGMP to 5  -guanosine monophos-
phate (GMP). By slowing the degradation of cGMP by 
PDE5, these drugs produce an intracellular accumulation 
of cGMP in smooth muscle cells in the corpus caverno-
sum and in the walls of the supplying arteries  [14] . Cur-
rently, vardenafil, sildenafil and tadalafil are marketed 
worldwide, while newer compounds such as udenafil and 
mirodenafil are approved in few countries while they are 
still in phase-3 trials elsewhere  [14] .
 As the endogenous production of NO is decreased in 
aging (vide supra), and further diminished by comorbid-
ities such as hypogonadism, diabetes and atherosclerosis, 
it logically follows that PDE5I have lower response rates 
in older than in younger patients  [14] . Nevertheless, they 
are recommended as the first-line pharmacotherapeutic 
option due to their ease of use, and excellent safety pro-
file, also in elderly  [36] . While some men report that 
PDE5I are not efficacious with first dose, results gener-
ally improve with repeated dosing. Patient education 
should cover this topic, address proper dosing intervals, 
and stress the fact that sexual stimulation is necessary for 
the drug to be effective  [9] . Overall efficacy rates are 60–
70% with on-demand treatment regimens  [5] . Of the pa-
tients that initially do not respond to PDE5I, between 30–
50% may be converted to responders by counseling the 
patient and his partner. Current recommendations ad-
vise starting treatment with a dose of 50 mg for sildenafil 
and 10 mg for vardenafil and tadalafil. Some patients who 
do not benefit from PDE5I therapy on demand, may ben-
efit from a daily low-dose administration  [37, 38] . For this 
indication, tadalafil is available for daily use in the 2.5 
and 5 mg dosage, and vardenafil was marketed in a 2.5 
mg daily dosage in some countries. Sildenafil has been 
used in clinical experimental setting in a daily dose of 25 
mg  [39] . In the aging male suffering from ED and late-
onset hypogonadism, addition of testosterone supple-
ments might enhance the efficacy of PDE5I therapy. This 
is based on the finding that physiological testosterone 
levels keep the erectile tissue and the supplying nerves in 
a healthy condition. Furthermore, testosterone increases 
the bioavailable NO in the cavernous smooth muscle and 
thus increases efficacy of PDE5 inhibition  [40] .
 The choice of PDE5I is basically up to the patient and 
partner, guided by the advice of the physician. Among the 
currently marketed agents, the most clinically significant 
differences are found in duration of action. The reported 
half-life of sildenafil and vardenafil are 4–6 h, while 
tadalafil has a longer bioactivity with a half-live time of 
17–21 h. The duration of activity that is seen with sildena-
fil and vardenafil appears to be suited to the average cou-
ples’ patterns of sexual interaction. Tadalafil has brought 
a shift in paradigm in treating ED and potentially enhanc-
es sexual spontaneity by the longer half-life time.
 The safety profile of the currently available PDE5I is 
excellent, based on post-marketing data and further dem-
onstrated by the recent FDA approvals for daily use of 
PDE5I, as mentioned above  [14] . In postmarketing phar-
macological surveillance, no increase in myocardial in-
farction rates in patients who received these agents has 
occurred compared to expected rates in age-matched 
populations  [14] . There are certain heart-related precau-
tions in the use of PDE5I which are important to note 
regarding the high prevalence of cardiac comorbidity in 
the aging male. PDE5I are relatively contraindicated in 
patients with unstable angina pectoris, recent myocar-
dial infarction, certain arrhythmias, and poorly con-
trolled hypertension. Patients who are treated with ni-
trates or nitrate donors should not take PDE5I, and usage 
of PDE5I with alpha-blockers may result in postural hy-
potension. The most common adverse events from PDE5I 
are attributable to specific inhibition of PDE5 and vaso-
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dilatation in tissues other than the penis, and include 
headache, facial and ocular hyperemia, nasal congestion, 
myalgia, and back pain. Visual blurring is a relatively fre-
quently occurring side effect which is attributed to cross-
reactivity with PDE6 in the retina. In a study assessing 
the safety of sildenafil in men aged 60–78, the most com-
monly experienced adverse events were flushing and dys-
pepsia, which occurred in 6.8 and 2.3%, respectively. No 
patients discontinued sildenafil treatment due to adverse 
events  [36] . In a retrospective study comparing the safety 
of vardenafil in patients aged 65 years or older with their 
younger counterparts, the most common treatment-
emergent adverse events were headache, rhinitis, flushing 
and dyspepsia, which were mild to moderate, transient 
and unrelated to age  [41] . Also for tadalafil, subgroup 
analysis in a large efficacy and safety study revealed no 
differences between the incidences of adverse events in 
tadalafil-treated men 65 years or older compared with 
younger men  [42] . In general, adverse events account for 
only a quarter of cases in which PDE5I are discontinued, 
while the most common reason for discontinuation of 
PDE5I is a lack of efficacy  [43] .
 Other Oral Pharmacotherapy 
 Apomorphine SL (Sublingual). Apomorphine is a cen-
trally acting nonselective dopamine agonist which en-
hances naturally occurring pro-erectile signals. It is ad-
ministered sublingually and rapidly absorbed into the 
systemic circulation. Therefore erections are achieved in 
approximately 20 min in the majority of the patients. It is 
available in two dosages, 2 and 3 mg. The most common 
adverse events include nausea, headache and dizziness 
and are due to nonspecific binding to various subtypes of 
the dopamine receptor. The relatively high frequency of 
adverse events has limited the clinical usefulness of the 
drug. Apomorphine is not contraindicated in patients 
taking nitrates, and therefore represents first-line oral 
treatment in this class of patients, although efficacy and 
tolerability are generally much lower than PDE5I  [44] . It 
is most effective in mild-moderate ED. As the severity of 
ED generally increases with advancing age, the clinical 
applicability of this dopamine agonist may be limited in 
aging patients. However, since it has a different mode of 
action compared to PDE5I, there may be a role for com-
bination therapy in patients who respond suboptimally to 
PDE5I and do not want to take the step to intracavernous 
or intraurethral therapy.
 Herbal Supplements. Herbal and nutritional supple-
ments generally lack strong evidence in the field of ED 
and should not be seen as a recommended mainstream 
medical therapy. Yohimbine is a peripherally and cen-
trally acting alpha-blocking alkanoid. It is derived from 
the bark of an evergreen tree along with some other psy-
choactive alkanoids. There is little evidence on its effi-
cacy, and it is therefore not generally recommended for 
management of ED. Ginseng is another widely known 
aphrodisiac which has been suggested to increase erectile 
function. Data on this substance are preliminary and 
need further trials. A third herbal substance may hold 
promise for the future therapy of ED; icariin is a flavonol 
glycoside and major constituent of horny goat weed. In 
China, horny goat weed, or  Herba  epimedii  has been used 
for centuries to enhance sexual drive and performance. 
Recently, it was discovered that this enhancement is due 
to an inhibitory effect of both PDE4 and PDE5 by icariin 
 [45] . Icariin was able to prevent fibrotic alterations in the 
corpus cavernosum after denervation in rats when ad-
ministered daily by oral gavage  [46] . Nutritional supple-
ments such as antioxidants may reduce erectile tissue 
damage by radical oxygen species  [47] . They have been 
suggested to enhance the efficacy of PDE5I, but this find-
ing needs to be validated in large-scale trials  [30] .
 Vacuum Constriction Devices 
 The vacuum constriction device is a manually oper-
ated device that creates negative pressure around the pe-
nis, resulting in passive engorgement of the sinusoidal 
spaces and the subcutaneous tissues. Its use is advised in 
patients who do not wish medical therapy for ED or in 
those who do not respond adequately to medical therapy 
and do not wish to undergo penile implantation surgery. 
Maintenance of erection is facilitated by application of a 
rubber cuff applied around the penile base. Although ef-
fective in up to 90% of patients, the use of a vacuum de-
vice might be perceived as disturbing. Patients should be 
counseled that erections achieved with a VCD do not ap-
pear natural but rather cool, cyanotic, and that instabil-
ity may occur as the turgidity occurs only distal to the 
constriction band  [48] . Local side effects are relatively 
minor and include bruising, some discomfort and ejacu-
latory obstruction. It is advised to limit the use of the 
constriction band to 30 min to avoid skin necrosis. Rela-
tive contraindications to VCD use include bleeding dis-
orders and the use of anticoagulants  [44] .
 Intracavernous and Intraurethral Administration of 
Vasoactive Substances 
 Before the advent of PDE5I in the late 1990s, intracav-
ernous and intraurethral administration of vasoactive 
substances were the only nonsurgical treatment options 
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for ED. It is the recommended second line treatment in 
patients that fail to respond PDE5I therapy. This treat-
ment provides an alternative with broad efficacy, good 
safety profile, and a rapid onset of action. The most com-
monly utilized substances include prostaglandin E1 
(PGE1), phentolamine, and papaverine. PGE1 and papav-
erine cause cavernous smooth muscle relaxation by eleva-
tion of the intracellular concentration of the second mes-
sengers cGMP and cyclic adenosine monophosphate. 
Phentolamine is an   -adrenergic antagonist. These 
mechanisms of action are independent of the endogenous 
supply of NO, and the substances are therefore suitable 
for older men who do not respond to PDE5I therapy. 
Overall satisfaction rates with intracavernous therapy are 
almost 80%. PGE1 is also available as an intraurethral 
administrated pellet (medicated urethral system/suppos-
itory for erection; MUSE  ). Urethral and intracavernosal 
administration of vasoactive substances results in erec-
tion within several minutes which last half an hour to
2 h, depending on the used dosage  [30, 44] . 
 Adverse events from these therapies include priapism, 
variable degrees of pain with injection in about half of 
patients, and penile fibrosis after long-term use. MUSE 
has been associated with hypotension, syncope, urethral 
burning or pain, and vaginal irritation in the partner. 
Relative contraindications to injection therapy include 
men who have a history of priapism and those with bleed-
ing disorders. If an erection lasts longer than 4 h, the pa-
tient is advised to seek advice of the treating physician 
 [44] .
 Surgical Treatment of ED 
 Surgical treatment is indicated in patients who have 
the desire to achieve erections and in whom conservative 
pharmacotherapy has failed, or those declining pharma-
cotherapy. While revascularization, venous ligation and 
reconstructive procedures have been described, these are 
reserved for the treatment of ED in young patients with 
specific indications  [30] . More commonly, a penile pros-
thesis is implanted.
 There are three types of penile prosthesis; 2- or 3-piece 
inflatable devices, semirigid devices, and soft silicone de-
vices. The latter technique is being abandoned as it was a 
supportive prosthesis and patients with partial ED now 
respond to pharmacotherapy. The three-piece inflatable 
prosthesis is currently the preferred device and consists 
of two inflatable rods, connected to a pump device which 
is placed in the scrotum and a reservoir which is placed 
in the preperitoneal space in the lower abdomen. The 
semirigid device is indicated in patients with limited 
manual dexterity and can be used when the patient is un-
able to undergo spinal or general anesthesia, as the cor-
pora cavernosa and the skin incision can be anesthetized 
locally. Both patient and partner satisfaction is very high 
and satisfaction rates reach 90–98% for the three-piece 
inflatable devices  [48] . Careful counseling before place-
ment of a penile prosthesis is of capital importance and 
limits postoperative dissatisfaction issues.
 Penile prosthesis placement is complicated by infec-
tion of the prosthesis in approximately 1–2% of the pa-
tients, but these percentages are decreasing due to novel 
coating techniques which allow the surgeon to immerse 
the device in an antibiotic solution of their choice. An-
other complication is prosthesis erosion, although this is 
quite rare in three-piece devices  [48] . Bothersome effects 
of penile prosthesis placement are auto-inflation, which 
can occur during increases of the intra-abdominal pres-
sure, and downward drooping of the glans due to lack of 
glandular engorgement during erection. Some patients 
also complain of erectile length loss with prosthesis place-
ment, especially in patients with Peyronie’s disease and 
after radical prostatectomy. The latter has been success-
fully treated with concomitant PDE5I therapy or MUSE 
pellet insertion  [48] . Currently implanted prostheses 
have reported survival times of approximately 60% after 
15 years  [48] .
 If Peyronie’s disease is diagnosed, it can be surgically 
treated, keeping in mind that surgery should be delayed 
until the disease has stabilized and curvature has not pro-
gressed for 6 months or longer  [30] . The Nesbit procedure 
used to be standard treatment, and consist of shortening 
the penis on the side opposite to the curvature to cancel 
out the amount of the curve. The Horton-Devine proce-
dure consists of resection of the plaque and replacement 
by a graft which can be of various origins (fascia lata, buc-
cal mucosa, porcine small intestinal submucosa xeno-
graft, etc). The third option, which is indicated in patients 
with Peyronie’s disease combined with severe ED, is the 
placement of a penile prosthesis, either or not in combi-
nation with other reconstructive surgeries.
 Future Directions in the Treatment of ED in the 
Aging Male 
 As mentioned above, the ED market is rapidly expand-
ing due to advancing age of the general population. This 
prospect has led to a surge in ED research which trans-
lates in an increasing body of literature advocating new 
therapeutic options for the condition. Pharmaceutical 
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ture research will improve our ability to provide for the 
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